argenex (NASDAQ:ARGX) Price Target Cut to $1,336.00 by Analysts at Wells Fargo & Company

argenex (NASDAQ:ARGX) had its price target cut by investment analysts at Wells Fargo & Company from $1,356.00 to $1,336.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 54.03% from the company’s current price.

Several other equities research analysts have also commented on ARGX. Sanford C. Bernstein restated a “buy” rating on shares of argenex in a research note on Thursday, October 8th. Robert W. Baird boosted their target price on shares of argenex from $823.00 to $861.00 and gave the stock a “neutral” rating in a report on Friday. Piper Sandler lifted their price target on argenex from $1,075.00 to $1,215.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. The Goldman Sachs Group reissued a “buy” rating on shares of argenex in a research note on Friday, September 25th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of argenex in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,148.95.

argenex Trading Down 1.0%

argenex stock traded down $8.42 during mid-day trading on Friday, reaching $867.34. The company’s stock had a trading volume of 57,760 shares, compared to its average volume of 351,519. The business has a 50 day moving average price of $956.17 and a 200-day moving average price of $885.45. argenex has a twelve month low of $661.85 and a twelve month high of $1,072.75. The firm has a market cap of $54.55 billion, a price-to-earnings ratio of 33.32, a PEG ratio of 0.82 and a beta of 0.44.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. argenex had a net margin of 32.19% and a return on equity of 43.59%. The business had revenue of $1.75 billion during the quarter. On average, equities analysts expect that argenex will post 28.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Guardian Partners Inc. acquired a new position in argenex in the third quarter valued at about $863,000. Sowell Financial Services LLC grew its holdings in shares of argenex by 25.8% during the third quarter. Sowell Financial Services LLC now owns 459 shares of the company’s stock worth $440,000 after purchasing an additional 94 shares during the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of argenex by 59.4% during the third quarter. Pinnacle Associates Ltd. now owns 757 shares of the company’s stock worth $726,000 after purchasing an additional 282 shares during the last quarter. Diversify Advisory Services LLC grew its holdings in shares of argenex by 32.5% during the third quarter. Diversify Advisory Services LLC now owns 2,911 shares of the company’s stock worth $2,791,000 after purchasing an additional 714 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC acquired a new position in shares of argenex during the third quarter worth approximately $236,000. Institutional investors own 60.32% of the company’s stock.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.